A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in ADHD

Attention-deficit/Hyperactivity Disorder Clinical Trial

Official title:

A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in Attention Deficit Hyperactivity Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02710929
• Other study ID #: 201412157RINA
• Status: Completed
• Start date: August 1, 2015
• Est. completion date: July 31, 2018

Study information

• Verified date: September 2021
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Specific Aims:

1. To find the genetic variations associated with spatial working memory performance in patients with ADHD by using genome-wide association studies (GWAS);

2. To find the genetic variations associated with spatial working memory performance in healthy subjects by using GWAS;

3. To recruit a validation sample and to replicate the findings from the initial GWAS;

4. To test whether genetic variations significantly associated with spatial working memory are also associated with ADHD.

Description:

Attention deficit hyperactivity disorder (ADHD), characterized by inattention, hyperactivity and impulsivity, is an early onset, highly heritable, clinically heterogeneous, long-term impairing disorder with tremendous impact on individuals, families, and societies. Our research team has conducted a series of biological studies on spatial working memory deficits of ADHD, and substantial evidence has suggested spatial working memory deficits as the important neuropsychological biomarker with translational values and favorable endophenotypic properties for ADHD. Despite the abundance of molecular genetic studies on ADHD, the genetic etiologies of ADHD have been non-conclusive. Because genetic studies on endophenotypes can offer more information on genetic and brain process, endophenotypic approach can efficiently enhance the statistical power and make genome-wide association studies (GWAS) applicable in much smaller sample. To date, there has been no GWAS study on spatial working memory deficits of ADHD.

This is a 3-year project. Our previous studies have collected blood samples and spatial working memory data of 382 patients with ADHD and 150 healthy subjects. In this 3-year project, we will recruit 232 healthy subjects, aged 7-18 years. The measures include (1) interviews for psychopathology (K-SADS-E), (2) questionnaires to measures ADHD symptoms (SNAP-IV), and (3) neuropsychological tests: Spatial Working Memory task of the CANTAB. In the first year, a case-only GWAS on spatial working memory (n = 254) will be conducted. In the second year, a control-only GWAS on spatial working memory (n = 254) will be conducted. In the third year, findings from the initial two GWAS will be replicated in a validation sample composed of 128 patients with ADHD and 128 healthy controls.

By careful calculation, a sample size of 382 ADHD subjects will provide adequate power to detect genome-wide significant genetic variations and replicate the findings in an independent validation sample. We anticipate to identify the relationship between genetic variations of ADHD and the endophenotype of spatial working memory. Our findings will significantly contribute to our understanding of the pathophysiological mechanisms of ADHD, especially the pathological pathway from genes, through endophenotype, to behavioral phenotypes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 232
• Est. completion date: July 31, 2018
• Est. primary completion date: July 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 7 Years to 18 Years

Eligibility

Inclusion Criteria:

• Subjects without any current or lifetime DSM-IV psychiatric disorders based on the K-SADS-E interviews.

Exclusion Criteria:

• Participants who had any past or current medical or neurological illness, who currently took psychotropic medication, or whose intelligence quotient (IQ) score was less than 80 were excluded.

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention-deficit/Hyperactivity Disorder
• Hyperkinesis

Locations

Country	Name	City	State
Taiwan	National Taiwan Univeristy Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychiatric interview	Subjects will be interviewed by Chinese Version of the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E)	1 hour
Secondary	Spatial working memory	Subjects will be assessed by the Cambridge Neuropsychological Test Automated Battery (CANTAB)	30 minutes